--- name: managing-immunization-protocols language: en description: Guides immunization administration with screening, scheduling, and documentation requirements. Use when administering vaccines, screening for contraindications, or documenting immunizations. tags: - management - pharmacy metadata: author: casemark practice_areas: - Clinical Pharmacy - Pharmacy document_types: - Management Report skill_modes: - Management - Coordination --- # Managing Immunization Protocols Guides immunization administration with screening, scheduling, contraindication assessment, and documentation requirements per CDC Advisory Committee on Immunization Practices (ACIP) recommendations. ## Why This Skill Exists Pharmacist-administered immunizations have expanded dramatically since the early 1990s, and all 50 states now authorize pharmacists to administer vaccines. During the COVID-19 pandemic, the PREP Act expanded pharmacist immunization authority further, and pharmacists administered over 300 million COVID-19 vaccine doses nationwide. Pharmacists are the most accessible healthcare providers—90% of Americans live within 5 miles of a community pharmacy—making them critical to achieving Healthy People 2030 immunization targets. The CDC's Advisory Committee on Immunization Practices (ACIP) publishes the annual recommended immunization schedules for children, adolescents, and adults. Pharmacists must screen for contraindications and precautions, administer vaccines per manufacturer specifications (route, site, needle gauge), observe patients for immediate adverse reactions, document in state immunization information systems (IIS), and report adverse events through the Vaccine Adverse Event Reporting System (VAERS). The National Childhood Vaccine Injury Act (NCVIA) requires provision of Vaccine Information Statements (VIS) before administration. Errors in immunization—wrong vaccine, wrong route, improper storage (cold chain break)—compromise protection and may require revaccination. --- ## Checkpoint A: Pre-Draft Intake (Mandatory) 1. What vaccine(s) are being considered? (Default: review patient immunization history against current ACIP schedule) 2. What is the patient's age? (Default: required for schedule determination) 3. What is the patient's immunization history (including dates of prior doses)? (Default: query state IIS) 4. Does the patient have contraindications or precautions? (Default: screen with CDC screening questionnaire) 5. Is the patient pregnant, immunocompromised, or recently received blood products? (Default: screen) 6. What is the patient's allergy history (eggs, gelatin, neomycin, latex, PEG, polysorbate)? (Default: review) 7. What state-specific pharmacist immunization authority applies? (Default: verify current state regulations) 8. Does the patient have insurance coverage for the vaccine? (Default: verify; VFC program for eligible children) ### Documents to Request - State immunization information system (IIS) history for the patient - Current ACIP recommended immunization schedule (adult or child/adolescent) - CDC Pre-Vaccination Screening Checklist (adults or children version) - Vaccine Information Statement (VIS) for each vaccine to be administered - Vaccine package insert (storage, preparation, route, dose, contraindications) - Allergy documentation from patient record - Standing order protocol (signed by authorized prescriber per state requirements) - Cold chain monitoring logs for vaccine storage units --- ## Step 1: Determine Vaccines Due Per ACIP Schedule **Adult immunization schedule (key vaccines and indications):** | Vaccine | Routine Schedule | Special Populations | |---|---|---| | Influenza (IIV/LAIV/RIV) | Annually, all adults | Egg allergy: RIV4 or IIV4 (any severity); LAIV contraindicated if immunocompromised | | Td/Tdap | Tdap once (if not received), then Td/Tdap q10y | Tdap during each pregnancy (27-36 weeks) | | Pneumococcal (PCV20 or PCV15+PPSV23) | Age ≥65 or risk conditions | PCV20 preferred one-dose series; PCV15 followed by PPSV23 if used | | Shingles (RZV) | Age ≥50 (2-dose series, 2-6 months apart) | Preferred over ZVL; safe in immunocompromised | | Hepatitis B (Hep B) | All adults 19-59; risk-based ≥60 | PreHevbrio (3-dose) or Heplisav-B (2-dose) for adults | | HPV | Through age 26 (catch-up to 45 shared decision) | 2-dose series if started before age 15; 3-dose if ≥15 | | COVID-19 | Per current CDC recommendations | Updated formulation per circulating variant; immunocompromised may need additional doses | | RSV | Age ≥60 (shared clinical decision); pregnancy (32-36 wks) | Seasonal administration (Abrysvo or Arexvy) | | Meningococcal ACWY | Risk-based (asplenia, complement deficiency, travel) | Required for college dormitory residents in many states | | Meningococcal B | Risk-based or shared clinical decision (ages 16-23) | Two or three dose series per product | **Catch-up dosing principles:** - Minimum intervals between doses must be respected; doses given too early must be repeated - There is no maximum interval; a lapsed series does not need to restart (except oral typhoid) - Document which dose in the series this represents (dose 1, 2, 3) --- ## Step 2: Pre-Vaccination Screening Use CDC Pre-Vaccination Screening Checklist. Screen for: **Absolute contraindications (do NOT administer):** - Severe allergic reaction (anaphylaxis) after a previous dose of the same vaccine or to a vaccine component - Known severe immunodeficiency for live vaccines (LAIV, MMR, varicella, yellow fever, oral polio) - Pregnancy for live vaccines **Precautions (generally defer; assess risk-benefit):** - Moderate or severe acute illness (defer until improved) - Recent blood product receipt (defer live vaccines per specific intervals: IVIG → wait 8-11 months for MMR/varicella) - Guillain-Barré syndrome within 6 weeks of prior influenza or Tdap vaccine - Thrombocytopenia or thrombotic thrombocytopenic purpura after prior dose **Common misconceptions (NOT contraindications):** - Mild illness with or without low-grade fever - Current antibiotic therapy (except for oral typhoid with certain antibiotics) - Disease exposure or convalescence - Pregnant or immunocompromised household contacts (can receive inactivated vaccines) - Breastfeeding (most vaccines safe) - Premature birth (vaccinate per chronological age) - Allergy to eggs (influenza vaccine safe for all egg-allergic patients per ACIP) --- ## Step 3: Vaccine Preparation and Administration **Cold chain verification:** - Check vaccine storage temperature log: refrigerator 2-8°C (36-46°F), freezer -50 to -15°C per vaccine - Inspect vaccine for particulate matter, discoloration, or expiration - Reconstitute per manufacturer instructions (use only supplied diluent) - Administer within manufacturer-specified time after reconstitution **Administration parameters:** | Vaccine Type | Route | Site (Adults) | Needle Gauge/Length | |---|---|---|---| | Most IM vaccines | Intramuscular | Deltoid | 22-25 gauge, 1-1.5 inch | | Live attenuated (LAIV) | Intranasal | Nares | Nasal sprayer | | IPV, some Hep A | IM or SC | Deltoid (IM) or triceps (SC) | IM: 22-25g, 1-1.5 in; SC: 23-25g, 5/8 in | | BCG, intradermal influenza | Intradermal | Deltoid region | 27 gauge, 3/8 inch | **Co-administration rules:** - Inactivated vaccines may be given simultaneously at different sites - Two live injectable vaccines must be given on the same day OR separated by ≥28 days - COVID-19 vaccines may be co-administered with other vaccines with no minimum interval - Use separate syringes and separate injection sites (≥1 inch apart) --- ## Step 4: Post-Administration Monitoring and Documentation **Observation period:** - Standard: 15 minutes post-vaccination for allergic reaction - Extended (30 minutes): History of anaphylaxis to any cause, history of syncope with injectable procedures, or after COVID-19 vaccination with specific precautions **Anaphylaxis management (must be available at all immunization sites):** - Epinephrine 1:1000 (1 mg/mL): 0.3-0.5 mg IM (adult) into anterolateral thigh - Repeat q5-15 min if needed - Call emergency services - Position patient supine with legs elevated **Required documentation:** 1. Vaccine name, manufacturer, lot number, expiration date 2. Date and site of administration 3. Route and dose 4. Name and title of person administering 5. VIS edition date and date provided to patient 6. Patient's name, date of birth, address 7. Report to state immunization information system (IIS) within required timeframe (typically 24-72h) **Vaccine Adverse Event Reporting System (VAERS):** - Report all adverse events listed on the VAERS Table of Reportable Events following vaccination - Report any clinically significant adverse event even if not on the table - Report online at vaers.hhs.gov; both patient and provider can report --- ## Step 5: Patient Education and Follow-Up - Provide and review the Vaccine Information Statement (VIS) for each vaccine administered (required by NCVIA) - Explain common side effects (injection site soreness, low-grade fever, fatigue) and expected duration (1-3 days) - Advise on return timing for next dose in multi-dose series - Provide immunization record card to patient - Schedule follow-up doses (shingles dose 2, hepatitis B series completion) - Recommend acetaminophen or ibuprofen for post-vaccination discomfort (avoid prophylactic antipyretics) --- ## Checkpoint B: Post-Draft Alignment (Mandatory) 1. Were all due vaccines identified per the current ACIP schedule and patient history? 2. Was the CDC Pre-Vaccination Screening Checklist completed and contraindications assessed? 3. Was the VIS provided and documented for each vaccine? 4. Were proper cold chain, preparation, and administration technique followed? 5. Was the immunization reported to the state IIS within the required timeframe? --- ## Quality Audit - [ ] Patient immunization history queried from state IIS before determining vaccines due - [ ] Vaccines due identified per current ACIP adult or pediatric schedule - [ ] CDC Pre-Vaccination Screening Checklist completed and documented - [ ] Contraindications and precautions assessed with clinical decision documented - [ ] Vaccine Information Statement (VIS) provided and date recorded - [ ] Vaccine storage temperature verified within range before administration - [ ] Correct vaccine, dose, route, and site verified - [ ] Lot number and expiration date recorded - [ ] Co-administration rules followed (live-live 28-day rule if not same day) - [ ] Post-vaccination observation period completed (15 or 30 minutes) - [ ] Epinephrine and emergency supplies available at vaccination site - [ ] Administration documented in patient record and state IIS - [ ] Follow-up doses scheduled for multi-dose series - [ ] VAERS report filed for any reportable adverse event - [ ] Standing order or prescription authority documented per state law --- ## Guidelines - Always query the state immunization information system (IIS) before administering—avoid duplicate vaccination - Egg allergy is NOT a contraindication to influenza vaccination per current ACIP guidance; any IIV or RIV can be administered - Two live injectable vaccines must be given on the same day OR separated by ≥28 days; this is a hard rule - Minimum intervals between doses must be respected; a dose given too early (<4 days before minimum) is invalid and must be repeated - VIS must be provided before EVERY vaccine administration; this is a federal legal requirement under NCVIA - Maintain cold chain integrity—once a vaccine has been temperature-excursion exposed, contact the manufacturer for guidance before discarding - Report all adverse events to VAERS regardless of causality certainty; VAERS is a signal-detection system, not a causality determination system - Pharmacist immunization scope varies by state; verify current authority, collaborative practice agreements, and reporting requirements